EGFR and non-small cell lung carcinoma: These findings suggest that the natural CypA inhibitors C9 and CsA may be attractive anticancer agents that effectively suppress the growth of EGFR-mutant NSCLC CSCs by interfering with the crosstalk between the CypA/CD147 and EGFR pathways.